诱导化疗后病理淋巴结阳性食管癌患者接受辅助化疗与生存改善相关
基于美国国家癌症数据库2006至2012年3100例诱导化疗±放疗后行食管切除术的病理淋巴结阳性食管癌患者,比较接受至少2周期辅助化疗(475例,15.3%)与未接受者(2625例,84.7%)的生存。辅助化疗组各病理N分期总生存均更优,且与死亡风险降低独立相关(HR 0.69,95%CI 0.57-0.83,P<.001)。
要点
- 病理淋巴结阳性患者中仅15.3%(475/3100)接受了至少2周期辅助化疗。
- 辅助化疗组N1期总生存31.6个月 vs 22.7个月(P<.001),N2期32.4个月 vs 19.2个月(P=.035),N3期19.5个月 vs 10.4个月(P<.001)。
- 辅助化疗与死亡风险降低独立相关(HR 0.69,95%CI 0.57-0.83,P<.001)。
核心结论
- 诱导治疗后行食管切除术的病理淋巴结阳性食管癌患者,接受辅助化疗在各阳性淋巴结分期均显示生存获益。
- 作者认为前瞻性研究可能有助于进一步明确该获益。
研究设计与样本
- 回顾性分析美国国家癌症数据库2006至2012年接受诱导化疗±放疗及食管切除术的食管癌患者。
- 病理淋巴结阳性患者按是否接受至少2周期辅助化疗或未接受辅助化疗分为两组。
- 采用Kaplan-Meier法绘制生存曲线,并以Cox比例风险模型分析总生存相关因素。
主要发现
- 共纳入3100例病理淋巴结阳性患者,其中2625例(84.7%)未接受辅助化疗,475例(15.3%)接受辅助化疗。
- N3期淋巴结分期与接受辅助化疗的可能性增加相关(参照N1期,比值比1.82,95%CI 1.15-2.97,P=.01)。
- 年龄增加(每岁,比值比0.97,95%CI 0.96-0.98,P<.001)、诱导放化疗(参照诱导化疗,比值比0.39,95%CI 0.30-0.52,P<.001)及食管切除术后住院时间延长(每天,比值比0.98,95%CI 0.97-0.99,P=.007)与接受辅助化疗的可能性降低相关。
- 辅助化疗组与未辅助化疗组总生存:N1期31.6个月 vs 22.7个月(P<.001),N2期32.4个月 vs 19.2个月(P=.035),N3期19.5个月 vs 10.4个月(P<.001)。
- 辅助治疗与死亡风险降低独立相关(风险比0.69,95%CI 0.57-0.83,P<.001)。
临床怎么用
- 原文未据此给出推荐。
- 作者结论指出,诱导治疗及食管切除术后接受辅助化疗的患者在各阳性淋巴结分期均显示生存获益,前瞻性研究可能有助于进一步明确该获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The study objectives were to identify variables associated with the use of adjuvant chemotherapy among patients with node-positive esophageal cancer who received induction therapy and to evaluate its relationship with overall survival. METHODS: Treatment data for patients with esophageal cancer receiving induction chemotherapy ± radiotherapy and esophagectomy were abstracted from the National Cancer Data Base. Pathologic node-positive patients were dichotomized by whether they received 2 or more cycles of adjuvant chemotherapy or none. Kaplan-Meier survival curves were generated, and a Cox proportional hazards model was done to identify factors associated with overall survival. RESULTS: From 2006 to 2012, 3100 patients had pathologic positive nodes after induction therapy and esophagectomy. A total of 2625 patients (84.7%) did not receive adjuvant chemotherapy, and 475 patients (15.3%) did. N3 nodal stage was associated with an increased likelihood of receiving adjuvant chemotherapy (reference: N1, odds ratio, 1.82, 95% confidence interval, 1.15-2.97, P = .01), whereas increasing age (by year, odds ratio, 0.97, confidence interval, 0.96-0.98, P < .001), induction chemoradiation therapy (reference: induction chemotherapy, odds ratio, 0.39, confidence interval, 0.30-0.52, P < .001), and increasing inpatient length of stay after esophagectomy (per day: odds ratio, 0.98, confidence interval, 0.97-0.99, P = .007) were associated with a decreased likelihood. Patients receiving adjuvant chemotherapy had improved overall survival at each pathologic nodal stage: 31.6 months versus 22.7 months for N1 disease (P < .001), 32.4 months versus 19.2 months for N2 disease (P = .035), and 19.5 months versus 10.4 months for N3 disease (P < .001). Adjuvant therapy was independently associated with decreased mortality hazard (hazard ratio, 0.69, 95% confidence interval, 0.57-0.83, P < .001). CONCLUSIONS: Patients receiving adjuvant chemotherapy after induction therapy and esophagectomy show a survival benefit at all positive nodal stages. Prospective studies may help further delineate this benefit.
引用
- Samson P, Puri V, Lockhart AC, et al. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival. J Thorac Cardiovasc Surg. 2018. PMID: 30054137. doi:10.1016/j.jtcvs.2018.05.100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。